新型抑酸药伏诺拉生根除幽门螺杆菌的研究进展  

Progress in the study on the eradication of Helicobacter pylori with a new acid inhibitor vonoprazan

作　　者：曾琳(综述) 聂刚(审校) ZENG Lin;NIE Gang(Department of Gastroenterology,University-Town Hospital of Chongqing Medical University,Chongqing 400000,China)

机构地区：[1]重庆医科大学附属大学城医院消化内科,重庆400000

出　　处：《中国临床新医学》2023年第11期1204-1209,共6页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

摘　　要：幽门螺杆菌(Hp)感染与慢性胃炎、消化性溃疡、胃黏膜相关淋巴组织淋巴瘤和胃癌等多种疾病相关,感染Hp的患者均应进行根除治疗。随着全球抗生素耐药率的提高,Hp根除率呈下降趋势,新的Hp根除方案有待被发掘。伏诺拉生(VPZ)作为一种新型钾离子竞争性酸阻滞剂,具有强效、稳定且持续的抑酸作用,对抗生素耐药的患者也能取得较好疗效,作为质子泵抑制剂的替代疗法已逐渐受到重视。该文就VPZ的作用机制、药理学特性及治疗研究现状等作一综述。Helicobacter pylori(Hp)infection is associated with various diseases such as chronic gastritis,peptic ulcer,gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer,etc,and all the patients infected with Hp should be given eradication treatment of Hp.As the global antibiotic resistance rate increases,the eradication rate of Hp decreases year by year,and new eradication schemes of Hp need to be excavated.Vonoprazan(VPZ),which is a novel potassium-competitive acid blockers,has strong,stable and long-lasting acid-suppressive effects.Patients with antibiotic resistance can also achieve a good effect when using VPZ.Its treatment as an alternative therapy of proton pump inhibitors has gradually gained serious attention.This paper reviews the mechanism of action,pharmacological properties and the therapeutic research status of VPZ.

关 键 词：幽门螺杆菌 伏诺拉生 质子泵抑制剂 研究进展 

分 类 号：R573.39[医药卫生—消化系统] R453.9[医药卫生—内科学]